Ionis Pharmaceuticals - IONS Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 2 sell ratings, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" IONS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares.
View IONS analyst ratings or view top-rated stocks.

7 Wall Street analysts have issued 1 year price targets for Ionis Pharmaceuticals' shares. Their IONS share price forecasts range from $30.00 to $64.00. On average, they anticipate the company's share price to reach $44.00 in the next year. This suggests a possible upside of 11.7% from the stock's current price.
View analysts price targets for IONS or view top-rated stocks among Wall Street analysts.

Ionis Pharmaceuticals' stock was trading at $37.77 at the beginning of the year. Since then, IONS shares have increased by 4.3% and is now trading at $39.38.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our IONS earnings forecast.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) released its quarterly earnings data on Wednesday, November, 9th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.41. The company earned $160 million during the quarter, compared to the consensus estimate of $149.48 million. Ionis Pharmaceuticals had a net margin of 0.91% and a trailing twelve-month return on equity of 1.18%.

Ionis Pharmaceuticals updated its FY 2022 earnings guidance on Friday, December, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $575.00M-, compared to the consensus revenue estimate of $594.45 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Ionis Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (1.88%), Allspring Global Investments Holdings LLC (0.34%), Assenagon Asset Management S.A. (0.31%), Baillie Gifford & Co. (0.23%), Peregrine Capital Management LLC (0.09%) and DAVENPORT & Co LLC (0.06%). Insiders that own company stock include B Lynne Parshall, Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke.
View institutional ownership trends.

Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IONS stock can currently be purchased for approximately $39.38.

Ionis Pharmaceuticals (NASDAQ:IONS) has a market capitalization of $5.59 billion and generates $810 million in revenue each year. The company earns $-28,600,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis.

The company employs 660 workers across the globe.

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The official website for the company is www.ionispharma.com. The company can be reached via phone at (760) 931-9200, via email at wwalke@ionisph.com, or via fax at 760-603-2700.